Related Experiment Video

Updated: Dec 14, 2025

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

19.8K

Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure

Imad Kassem1,2, Steven Sanche1, Jun Li1,3

  • 1Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.

Clinical and Translational Science
|July 24, 2020
PubMed

Insights

This study examined candesartan pharmacokinetics in heart failure (HF) patients. Factors like weight, eGFR, and diabetes significantly impact drug clearance, suggesting personalized dosing is needed for effective HF treatment.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Cardiology

Background:

  • Heart failure (HF) alters drug pharmacokinetics (PK) due to organ dysfunction.
  • Understanding drug behavior in HF is crucial for effective treatment.
  • Candesartan is commonly prescribed for HF, but its PK variability needs investigation.

Purpose of the Study:

  • To investigate the population pharmacokinetics (Pop-PK) of candesartan in patients with heart failure.
  • To identify covariates affecting candesartan's apparent oral clearance (CL/F).
  • To inform individualized dosing strategies for candesartan in HF.

Main Methods:

  • Population PK modeling using NONMEM and R software.
  • Analysis of data from a prospective, multicenter study.
  • Inclusion of 281 white patients in the model development.

Main Results:

  • The final Pop-PK model for candesartan CL/F incorporated weight, estimated glomerular filtration rate (eGFR), and diabetes.
  • These factors explained a portion of the interindividual variability in CL/F.
  • Simulations indicated a >25% decrease in CL/F when these covariates were present.

Conclusions:

  • Weight, eGFR, and diabetes are significant predictors of candesartan clearance in HF patients.
  • These findings support the need for individualized dosing of candesartan.
  • Further investigation into personalized dosing regimens is warranted for optimal patient outcomes.

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

450
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.2K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
771
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
131
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
706
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
646
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
557